NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Arialys Therapeutics

Arialys Therapeutics

Private
La Jolla, CaliforniaHealthcare & Life Scienceshttps://arialysrx.com/

Last Round

Seed

Sep 12, 2023

Total Funding Raised

$58M

Company Overview

Arialys Therapeutics is a biotechnology company that develops precision medicines to treat autoimmune neuropsychiatric diseases by blocking pathogenic autoantibodies in the brain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision medicineanti-NMDA receptor encephalitisANREbiotechautoimmune neuropsychiatric diseasetherapeutic candidateclinical-stage biotechorphan drugmonovalent antibodyrare disease therapydrug developmentclinical trialFDA fast trackbiopharmadrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arialys Therapeutics Comparables

Compare Arialys Therapeutics with similar companies based on industry and business-model similarity.

Arialys Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Santa Ana Bio
63%
STALICLA
62%
Roche Holding
61%

Arialys Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 12, 2023

Key People

Founding team and executive leadership

Mitsuyuki MATSUMOTO

Scientific Founder & Chief Scientific Officer

Founding Team

Peter Flynn

President And Chief Executive Officer

Executive Team

Arialys Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 12, 2023

    $58M round led by Johnson & Johnson Innovation and Avalon BioVentures.

Arialys Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Arialys Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Arialys Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLa Jolla, California
Employee Range14
Year Founded2021
Last FundingSep 12, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.